IL-17和IL-35水平与甲状腺癌关系的Meta分析

目的 探讨白细胞介素(interleukin,IL)-17和IL-35水平与甲状腺癌的关系.方法 应用计算机检索PubMed、中国知网和万方数据库自200年1月至2016年12月关于IL-17和IL-35水平与甲状腺癌关系的临床对照试验.按纳入和排除标准选择文献,提取数据.采用Stata12.0软件对纳入文献进行Meta分析.结果 纳入文献5篇,样本量409例.与对照组比较甲状腺癌患者IL-17水平明显增加[WMD=6.31, 95%CI(5.89, 6.73)],而IL-35水平明显减低[WMD=-8.52, 95%CI(-9.40, -7.63)],其差异均具有统计学意义(P均<0.05).结论 现有证据表明IL-17和IL-35水平与甲状腺癌的关系密切,其可为甲状腺癌的诊断、治疗和预后提供依据.

Meta Analysis of the Relationship Between IL-17 and IL-35Levels and Thyroid Carcinoma

Objective To investigate the relationship between IL-17 and IL-35 levels and thyroid carcinoma.Methods Data of clinical trials about the relationship between the IL-17 and IL-35 levels and thyroid cancer were collected from CNKI, Wanfang Chinese and PubMed up to December 2016.Data were selected according to inclusion and exclusion criteria.Stata12.0 software was used for Meta analysis.Results 5 articles were included in the study, and the sample size was 409 cases.Compared with the control group, the level of IL-17 in thyroid cancer patients was significantly increased [WMD=6.31, 95%CI (5.89, 6.73)], while the level of IL-35 was significantly reduced [WMD=-8.52, 95%CI (-9.40, -7.63)].And the difference was statistically significant (P =0.05).Conclusion Available evidence suggests that IL-17 and IL-35 levels are closely related to thyroid cancer, which can provide the accordance for diagnosis, treatment and prognosis of thyroid carcinoma.